Canaccord analyst Sumant Kulkarni upgraded Neurocrine to Buy from Hold with a price target of $132, up from $124.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on NBIX:
- Neurocrine added to Analyst Focus List at JPMorgan
- Teva’s CP trial failure may add some risk for Neurocrine, says RBC Capital
- Neurocrine announces results of published study on tardive dyskinesia
- Neurocrine to present data on Ingrezza capsule dissolution performance
- ‘2023 Rally Was a Bull Trap,’ Says Morgan Stanley. But These Stocks Still Have Upside